Occlusion of the portal liver vein to permit liver surgeries for liver cancer

Portal vein embolization with n-butyl-cyanoacrylate through an ipsilateral approach before major hepatectomy: single center retrospective analysis of 50 consecutive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN39855523

Enrollment

Registered

2017-03-13

Start date

2011-02-01

Completion date

Unknown

Last updated

2017-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary and secondary liver cancer Cancer Primary and secondary liver cancer

Interventions

This retrospective review study consists of participants that have been referred to have a portal vein embolization. Participants have the procedure which includes involves an ultrasounded guided punc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with primary and secondary liver cancer treatable by hepatectomy 2. Proportion of FLR volume to the total functional liver volume (TFLV) less than 25% or less than 40% in patients with previous chemotherapy or hepatic cirrhosis. 3. Aged between five to 75 years old

Exclusion criteria

Exclusion criteria: 1. Extensive ipsilateral tumor precluding safe access to the portal vein 2. Unmanageable coagulopathy 3. Extensive extra-hepatic disease 4. Liver abscess or infection

Design outcomes

Primary

Measure	Time frame
Growth of the future liver remnant is measured using the Future Liver Remnant (FLR) volume changes, growth rate and kinetic growth rate obtained from the Volumetric Computer Tomography of the liver at one and four weeks after portal vein embolization.	—

Secondary

Measure	Time frame
1. Accomplishment of hepatectomy is measured using patients medical charts at weeks four to six after portal vein embolization 2. Patient out-come after hepatectomy is measured using patients medical charts at baseline, week two, week four and every three months for five years 3. Safety of the proposed PVE technique measured using patients medical charts during their hospitalization stay after portal vein embolization	—

Measure

Time frame

1. Accomplishment of hepatectomy is measured using patients medical charts at weeks four to six after portal vein embolization 2. Patient out-come after hepatectomy is measured using patients medical charts at baseline, week two, week four and every three months for five years 3. Safety of the proposed PVE technique measured using patients medical charts during their hospitalization stay after portal vein embolization

—

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 26, 2026